story of the week
Racial Disparities in Overall Survival After the Introduction of CDK4/6 Inhibitors for Patients With HR+/HER2− Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Breast Cancer Research and Treatment
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Racial disparities in overall survival after the introduction of cyclin-dependent kinase 4/6 inhibitors for patients with hormone receptor-positive, HER2-negative metastatic breast cancer
Breast Cancer Res Treat 2023 Feb 01;198(1)75-88, A Alvarez, AM Bernal, J AnampaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.